Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Set to Buy More Chinese Drugs (China)

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca has announced it will join the ranks of drug manufacturers choosing to obtain raw materials and active pharmaceutical ingredients from emerging Asian markets. Over the next three years, the company's Chinese contracts will grow from $10 million to $100 million. AstraZeneca has also announced intentions to enact a similar investment plan in India's drug manufacturing industry. The company's move is part of a larger goal to reduce drug production costs, in an effort to keep business lucrative. The industry's renewed respect for the bottom line comes as the result of fierce generic competition and dwindling global patent protection for brand-name drugs. Still, many companies are daunted by a lack of production safety standards and intellectual property rights in some countries. But the promise of improvements in regulatory conditions are making outsourcing to countries like China and India a hard deal for manufacturers to resist. (Click here for more - May Require Paid Subscription

You may also be interested in...

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts